Oct 23, 2023, 13:31
At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma
Agenus shared on their LinkedIn page:
“At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab (BOT/BAL) combination in relapsed/refractory sarcoma, which showed durable responses across multiple subtypes. The results reinforce the potential of BOT/BAL in multiple cold, treatment-resistant solid tumors. Learn more here.”
Source: Agenus/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 11, 2024, 09:15
Dec 11, 2024, 09:10
Dec 11, 2024, 08:56
Dec 11, 2024, 08:00
Dec 11, 2024, 07:55
Dec 11, 2024, 06:31
Dec 11, 2024, 06:29
Dec 11, 2024, 05:28